Mechanisms underlying aberrant expression of miR-29c in uterine leiomyoma
Mechanisms underlying aberrant expression of miR-29c in uterine leiomyoma
复制标题
DOI:
10.1016/j.fertnstert.2015.09.020
复制
发表时间:
2016-01-01
影响因子:
6.7
通讯作者:
Khorram, Omid
中科院分区:
文献类型:
--
作者:
Chuang, Tsai-Der;Khorram, Omid
Objective: To determine the expression of miR-29c and its target genes in leiomyoma and the role of NF-kappa B, specific protein 1 (SP1), and DNA methylation in its regulation.Design: Experimental study.Setting: Academic research laboratory.Patient(s): Women undergoing hysterectomy for leiomyoma.Intervention(s): Over-and underexpression of miR-29c; blockade of transcription factors.Main Outcome Measure(s): MiR-29c and its target gene levels in leiomyoma and the effects of blockade of transcription factors on miR-29c expression.Result(s): Leiomyoma as compared with myometrium expressed significantly lower levels of miR-29c, with an inverse relationship with expression of its targets, COL3A1 and DNMT3A. Gain of function of miR-29c inhibited the expression of COL3A1 and DNMT3A at protein and mRNA levels, secreted COL3A1, and rate of cell proliferation. Loss of function of miR-29c had the opposite effect. E-2, P, and their combination inhibited miR-29c in leiomyoma smooth muscle cells (LSMC). Phosphorylated NF-kappa B (p65) and SP1 protein expression were significantly increased in leiomyoma. SiRNA knockdown of SP1 and DNMT3A or their specific inhibitors significantly increased the expression of miR-29c, accompanied by the inhibition of cellular and secreted COL3A1 in siRNA-treated cells. Knockdown of p65 also induced miR-29c expression but had no effect on COL3A1 expression.Conclusion(s): MiR-29c expression is suppressed in leiomyoma, resulting in an increase in expression of its targets COL3A1 and DNMT3A. The suppression of miR-29c in LSMC is primarily mediated by SP1, NF-kB signaling, and epigenetic modification. Collectively, these results indicate a significant role for miR-29c in leiomyoma pathogenesis. (C) 2016 by American Society for Reproductive Medicine.